G-SPACE proposes a new process that integrates microgravity and artificial intelligence (AI) into a real-time analysis solution with potential future endeavors to become a predictive capability. This process will allow informed experimental tests and ultimately drug therapy decisions to be systematically discovered. The platform's user interface will allow researchers to easily design and execute experiments, monitor results, and refine their hypotheses. The platform's capabilities will significantly reduce drug discovery timelines, increase the success rate of drug candidates, and ultimately improve patient outcomes. In partnership with Micro-gRx, G-SPACE proposes this feasibility study to demonstrate its platform use to the simulation of sarcopenia conditions both terrestrially and in-space, which have been shown to enhance cellular functions relevant to drug discovery and eventual FDA approval. Currently there are No FDA approved drugs for sarcopenia. A hallmark of sarcopenia is a progressive pathology characterized by the loss of muscle mass and strength in those over 60 years old. The age-related effects on muscle tissue is difficult to model in cell systems because of genetic differences and tissue heterogeneity in patients and it is most desirable to eliminate reliance on animal studies. The unmet medical need is a standardized platform that can provide a solid reference and evaluate patient-specific tissue pathophysiological responses to potential therapeutics in real time. Anticipated
Benefits: The G-Space analytic platform will help the NASA microgravity R&D community to make an accelerated shift towards translation of microgravity science into applications. The G-SPACE “microgravity explorer” version will increase access and understanding of the potential benefits of microgravity to non-traditional commercial players and stimulate terrestrial demand. The proposed study will demonstrate the value of G-SPACE AI software platform to TOC through validation via the Micro-gRx MPS systems. The products will be essential in ensuring that the muscle MPS can meet FDA requirements for certification and provide a standardized way to evaluate the degradation process and the effectiveness of various drugs and methods. As the database grows, the model will ultimately allow for widespread access to this groundbreaking technology.
